Clinical Trial Update: To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination

View source ↗

Summary

A completed clinical trial evaluating safety and reactogenicity of GSK's human rotavirus vaccine in Filipino infants starting at 6 weeks of age.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rotavirus Infections

Drugs mentioned

• HRV vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Rotavirus, Rotavirus Vaccines | Status: COMPLETED | Results posted: 2011-08-03